| Literature DB >> 29084894 |
Joseph U Igietseme1,2, Yusuf Omosun3,2, Tamas Nagy4, Olga Stuchlik3, Matthew S Reed3, Qing He3,2, James Partin3, Kahaliah Joseph3, Debra Ellerson3, Zenas George3, Jason Goldstein3, Francis O Eko2, Claudiu Bandea3, Jan Pohl3, Carolyn M Black3.
Abstract
The reproductive system complications of genital chlamydial infection include fallopian tube fibrosis and tubal factor infertility. However, the molecular pathogenesis of these complications remains poorly understood. The induction of pathogenic epithelial-mesenchymal transition (EMT) through microRNA (miRNA) dysregulation was recently proposed as the pathogenic basis of chlamydial complications. Focusing on fibrogenesis, we investigated the hypothesis that chlamydia-induced fibrosis is caused by EMT-driven generation of myofibroblasts, the effector cells of fibrosis that produce excessive extracellular matrix (ECM) proteins. The results revealed that the targets of a major category of altered miRNAs during chlamydial infection are key components of the pathophysiological process of fibrogenesis; these target molecules include collagen types I, III, and IV, transforming growth factor β (TGF-β), TGF-β receptor 1 (TGF-βR1), connective tissue growth factor (CTGF), E-cadherin, SRY-box 7 (SOX7), and NFAT (nuclear factor of activated T cells) kinase dual-specificity tyrosine (Y) phosphorylation-regulated kinase 1a (Dyrk1a). Chlamydial induction of EMT resulted in the generation of α-smooth muscle actin (α-SMA)-positive myofibroblasts that produced ECM proteins, including collagen types I and III and fibronectin. Furthermore, the inhibition of EMT prevented the generation of myofibroblasts and production of ECM proteins during chlamydial infection. These findings may provide useful avenues for targeting EMT or specific components of the EMT pathways as a therapeutic intervention strategy to prevent chlamydia-related complications.Entities:
Keywords: Chlamydia; Chlamydia trachomatis; epithelial-mesenchymal transition (EMT); extracellular matrix proteins; fibrosis; miRNAs; myofibroblasts
Mesh:
Substances:
Year: 2017 PMID: 29084894 PMCID: PMC5736829 DOI: 10.1128/IAI.00585-17
Source DB: PubMed Journal: Infect Immun ISSN: 0019-9567 Impact factor: 3.441